Digital Health Investment Weekly Report Vol.178 Files for IPO
Restor3d
3D Printing Implant Supplier
ProVerum
Developer of Novel Minimally Invasive Technologies
Twin Health
Health Service Platform Developer
Wellth
Internet Health Management Platform Provider
Vaxxas
Nanopatch Developer
01 Global Digital Health Investment and Financing Overview
3D Printing Implant Supplier Restor3d Secures $104 Million in Financing
On August 22, 3D-printed implant supplier Restor3d secured $104 million in financing, led by Partners Group with additional investment from existing shareholders. Restor3d enables surgeons to improve the reconstruction and repair of the human body through 3D-printed implants, enhancing anatomical fit and superior integration.
ProVerum, a developer of treatment solutions for benign prostatic hyperplasia (BPH), secures $80 million in Series B financing
On August 25, ProVerum, a developer of benign prostatic hyperplasia (BPH) treatment solutions, secured $80 million in Series B funding led by MVM Partners, with new investors OrbiMed and the Ireland Strategic Investment Fund (ISIF) joining, as well as participation from existing investors such as Gilde Healthcare Partners. The proceeds will be used to advance the commercialization of ProVerum's ProVee® system, a minimally invasive solution for treating BPH.
Twin Health, Inc. Secures $53 Million in Funding for Health Service Platform Development
On August 21, health service platform developer Twin Health secured $53 million in funding, led by Maj Invest. This round of financing will be used to accelerate Twin's expansion in retail, healthcare, financial services, technology, and manufacturing sectors, as well as among Fortune 500 clients. Its AI digital twin technology achieves sustainable treatment outcomes for diabetes and obesity while reducing medication use.
Wellth, Inc. Secures $36 Million in Series C Funding for Internet Health Management Platform
On August 21, Wellth, an internet health management platform provider, secured $36 million in Series C funding. The round was led by Mercato Partners, with participation from FCA Venture Partners, Comcast Ventures, and existing investors SignalFire, NY Life, and CD-Venture. The funds will be used to expand the reach of its application among Medicare Advantage, Medicaid, D-SNP, and other high-demand populations, while accelerating product innovation and partner growth.
Nanopatch Developer Vaxxas Secures $31.9 Million in Financing
On August 25, Vaxxas, a developer of nano-patch technology, secured $31.9 million in funding led by SPRIM Global Investments, with participation from new investor LGT Crestone and existing investors OneVentures and Brandon Capital-Hostplus. The funds will be used to accelerate the development and scaling of HD-MAP technology, including the installation of semi-automated production lines and late-stage clinical trial plans.
Biological Active Ingredient Developer Debut Secures $20 Million in Financing
On August 26, biologically active ingredient developer Debut secured $20 million in funding from investors including Fine Structure Ventures, EDBI, Wealthberry, and BOLD (L'Oréal's venture capital fund). The proceeds will primarily be used to accelerate AI-driven ingredient discovery in the field of skin longevity and expand its formulation business in the U.S. and Asia.
Vision Testing Technology Developer Eyebot Secures $20 Million in Series A Funding
On August 26, Eyebot, a vision testing technology developer, secured $20 million in Series A funding, led by General Catalyst, with participation from AlleyCorp, Baukunst, Village Global, and others. The funds will be used to expand access to vision care, support partnerships across the U.S., drive product innovation, and foster team growth.
MRI Equipment Developer Pusiying Medical Secures Nearly RMB100 Million in Series A Funding
On August 28, Pusiying Medical, a developer of MRI equipment, secured nearly RMB 100 million in its Series A round of financing led by Ivy Capital, with continued investment from existing shareholder Neusoft Capital and participation from Xiaoming Investment. The proceeds will be used to accelerate the industrial application and expansion of the low-helium PhaseXCool® siphon cooling technology in superconducting magnet devices, covering three major areas: medical magnetic resonance imaging (MRI) equipment, industrial magnetic single-crystal pulling superconducting magnet systems, and precision scientific instruments.
Boron Neutron Capture Therapy (BNCT) Developer Hua Boron Neutron Secures Pre-A Round Funding Worth Hundreds of Millions of RMB
On August 22, Huaborong Neutron, a developer of boron neutron capture therapy (BNCT) technology, secured hundreds of millions of RMB in Pre-A funding. The round was jointly led by Wuchan Zhongda Hongcheng Investment and its affiliates (Taizhou Circular Economy, Zhegu Group, Huadian Investment) along with Kaitai Capital, with participation from Huzhou Industrial Investment, Anfeng Venture Capital, and Caitong Capital, among other institutions. The proceeds will primarily be used to accelerate the company’s clinical trial research, the development of new boron drugs, and the commercial promotion and implementation of BNCT equipment.
Full-Family Healthcare Provider Nest Health Secures $12.5 Million in Series A Funding
On August 25, Nest Health, a full-family healthcare provider, secured $12.5 million in Series A funding, co-led by 8VC and Blue Venture Fund, with participation from new investor Amboy Street Ventures and follow-on investments from Alumni Ventures and others. The funds will be used to expand Nest Health's Medicaid home care model, leveraging artificial intelligence to deliver care for the right needs at the right time, and to broaden its services to new regions through collaborations with additional payers.
Medical Record System Software Developer Barti Software Secures $12 Million in Series A Funding
On August 25, Barti Software, a medical records system software developer, secured $12 million in Series A funding, led by Five Elms Capital. The funds will be used to accelerate the advancement of AI electronic health record systems for ophthalmic care, expand market promotion efforts, grow the team in key functional areas, and expedite the development of new artificial intelligence features and workflow automation.
AI-Driven Large Molecule Drug Developer Xinhua Bio Completes Multi-Million Dollar Series A Financing
On August 25, VAXXAS, an AI-driven large molecule drug developer, completed a multi-million-dollar Series A round of financing. The A+ round was led by Apricot Capital, while the A round was led by Sanyi Innovation Investment, with follow-on investments from Sequoia China and other existing shareholders. The funds will primarily be used to advance the company’s core pipeline into global clinical trials and accelerate the research and development process of First-in-Class (FIC) and Best-in-Class (BIC) drugs.
Reproductive Health Service Provider Xiduo International Medical Receives 25 Million Yuan in Series A Financing
On August 27, Xiduo International Medical, a provider of reproductive health services, secured RMB 25 million in its Series A round of financing, invested by Shenzhen Guanfeng Yongyue Investment Co., Ltd. This round of financing will mainly be used for deepening the integration of international medical resources, expanding the service chain, and building a digital platform.
Rhovica Neuroimaging, developer of the external ventricular drain (EVD), secures CHF 2.3 million in funding
On August 26, Rhovica Neuroimaging, the developer of external ventricular drain (EVD), secured CHF 2.3 million in funding led by M2care, with participation from Kickfund, Valuemaker, and several business angels. This funding will accelerate the development of Rhovica's bedside navigation system, SoNav, which is used for life-saving drainage catheters in emergency neurosurgical procedures.
Teda Bio and Suihong Huachuang Sign Agreement to Collaborate on AI Healthcare Business
On August 27, Teda Bio (08189.HK) signed a strategic cooperation agreement in the AI medical health field with Suihong Huachuang, a subsidiary of Hongxin Electronics (300657). This collaboration will accelerate Teda Bio's research and commercialization of AI medical large models and related businesses, leveraging Suihong Huachuang’s accumulated government cooperation and mature sales channels from its intelligent computing center construction business. This will support the market promotion of Teda Bio's AI medical large models and related data services. Additionally, both parties will jointly invest in the research and innovation of an integrated AI medical health machine, promoting the widespread application of NVIDIA’s ecosystem, China-produced ecosystem, and Suihong’s integrated machines in the AI medical health sector.
Vivant Health Partners with Pandia Health to Expand Women's Health Services and Promote Health Equity
On August 25, Vivant Health partnered with Pandia Health to expand access to women's health services and promote health equity. Pandia Health, a telehealth provider founded and led by women, focuses on improving women’s access to comprehensive healthcare. This collaboration will offer Vivant Health members easier access to Pandia Health’s online care from expert doctors and medication delivery services, including telehealth consultations, convenient prescription refills, and private delivery of FDA-approved medications.
Medical Imaging Workflow Solutions Provider Core Sound Imaging Acquires UltraLinQ
On August 26, Core Sound Imaging, a provider of medical imaging workflow solutions, acquired UltraLinQ, a cloud-based PACS and cardiac monitoring solutions provider serving over 70,000 users across more than 8,000 sites. Core Sound Imaging, with its scalable and intuitive medical imaging workflow platform Studycast, will now support a broader range of healthcare providers, benefiting everyone from small clinics to large hospital networks.
Pharmaceutical Commercialization Services Provider EVERSANA Acquires Waltz Health
On August 26, pharmaceutical commercialization services provider EVERSANA (the parent company of Pharmaphorum) acquired digital health company Waltz Health, which offers an AI-driven marketplace platform to reduce overall drug costs. This acquisition will enable EVERSANA to expand its efforts in creating end-to-end commercialization services for pharmaceutical companies by directly connecting life sciences companies with payers.
Laboratory and Pathology Services Provider Sonic Healthcare USA Acquires Cairo Diagnostics
On August 22, Sonic Healthcare USA, a provider of laboratory and pathology services, acquired Cairo Diagnostics, a comprehensive hematology oncology diagnostics supplier. This acquisition will enable SHUSA to integrate Cairo's medically-led test menu and infrastructure into its nationwide network, supported by SHUSA’s logistics, payer contracting, and commercial organization.
Precision Medicine Tech Researcher Tempus Acquires Paige.AI for $81.25 Million
On August 22, precision medical technology researcher Tempus acquired AI cancer diagnostics technology developer Paige.AI for $81.25 million. Paige possesses one of the world's most comprehensive digital pathology datasets, and this acquisition aims to expand Tempus’s dataset and establish a strong presence in the digital pathology field.
Mental Health and Wellness Solutions Provider Uwill Acquires tbh
On August 21, mental health and wellness solutions provider Uwill acquired mental health care services provider tbh. This acquisition reflects the ongoing expansion of the Uwill platform to offer students comprehensive mental health support. Already widely used by universities, K12 school districts, and employers, tbh’s platform will add a new dimension to Uwill’s mental health and wellness environment.
ArteryNet/Arterial Orange Industry Think Tank/Huaxing Capital/ BGI Co-Win / Rock Health / Mobile Health News / Fierce Health, etc.
Share
Like
Click to view